Krystal Biotech KRYS
NASDAQ KRYS
$308.81 +2.31 (+0.75%)
At close: Nov 11, 2026 · 4:00 PM EST

Krystal Biotech (KRYS) EV to EBITDA (2024 - 2026)

Updated

Krystal Biotech's (KRYS) EV to EBITDA was 38.30 for Q3 2026, up 43.2% from 26.76 a year earlier but down 23.2% from the prior quarter.

Analysis

Krystal Biotech (KRYS) EV to EBITDA (2024 - 2026) Analysis & Trends

Over the twelve months ended Sep 30, 2026, Krystal Biotech's EV to EBITDA came in at 27.61, up 81.8% year-over-year; for FY2025, it was 38.13, down 30.1% from FY2024.

  • By year, EV to EBITDA came in at 54.54 in FY2024.
  • Five-year quarterly EV to EBITDA spans a low of 22.73 in Q2 2025 and a high of 138.14 in Q3 2024.
  • Year over year, EV to EBITDA gained in two of the last five quarters, with growth averaging 8.7%.
  • Per Business Quant data, the three quarters before Q3 2026 came in at 49.87 (Q2 2026), 36.76 (Q1 2026) and 38.16 (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Krystal Biotech 9.08 Bn 5.67 Bn 119.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 38.30
Jun 30, 2026 49.87
Mar 31, 2026 36.76
Dec 31, 2025 38.16
Sep 30, 2025 26.76
Jun 30, 2025 22.73
Mar 31, 2025 40.09
Dec 31, 2024 54.62
Sep 30, 2024 138.14
API Access

Krystal Biotech EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=KRYS&period=max&api_key=YOUR_API_KEY